RxDoctor Payments Data

Alberto Guardiola, MD

Ophthalmology · Mayaguez, PRNPI 1144426230

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 27 payments — averaging $52.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$330
  • Alcon Puerto Rico Inc$310
  • Genentech USA, Inc.$304
  • Regeneron Healthcare Solutions, Inc.$207
  • AbbVie$69
  • Alcon$52
  • plus $146 from 5 others

What the payments were for

  • Food & beverage$1,23887%
  • Education$18113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 70th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$36,111
Medicare patients
90
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine154$95,381
LumiganBimatoprost130$39,706
Cyclosporine124$24,812
Prednisolone Acetate510$22,379
OzurdexDexamethasone11$16,933
Latanoprost1,394$16,048
Dorzolamide Hcl390$11,346
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol70$9,315
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat223$7,895
Brimonidine Tartrate431$7,004
Atropine Sulfate159$5,523
AzoptBrinzolamide14$5,183
Fluorometholone77$5,128
CombiganBrimonidine Tartrate/Timolol23$4,760
SimbrinzaBrinzolamide/Brimonidine Tart21$4,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Ozurdex, Combigan$69$156,781318 claims
AlconAzopt, Simbrinza$52$9,57835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →